- Home
- TPR vs UTHR Comparison
TPR vs UTHR Comparison
Compare TPR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPR
- UTHR
- Stock Information
- Founded
- TPR 1941
- UTHR 1996
- Country
- TPR United States
- UTHR United States
- Employees
- TPR N/A
- UTHR N/A
- Industry
- TPR Apparel
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- TPR Consumer Discretionary
- UTHR Health Care
- Exchange
- TPR Nasdaq
- UTHR Nasdaq
- Market Cap
- TPR 16.8B
- UTHR 14.4B
- IPO Year
- TPR 2000
- UTHR 1999
- Fundamental
- Price
- TPR $77.54
- UTHR $308.93
- Analyst Decision
- TPR Buy
- UTHR Buy
- Analyst Count
- TPR 18
- UTHR 12
- Target Price
- TPR $80.17
- UTHR $392.00
- AVG Volume (30 Days)
- TPR 5.0M
- UTHR 439.7K
- Earning Date
- TPR 05-08-2025
- UTHR 04-30-2025
- Dividend Yield
- TPR 1.81%
- UTHR N/A
- EPS Growth
- TPR 0.55
- UTHR 18.86
- EPS
- TPR 3.79
- UTHR 25.10
- Revenue
- TPR $6,878,600,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- TPR $4.07
- UTHR $11.45
- Revenue Next Year
- TPR $2.78
- UTHR $6.11
- P/E Ratio
- TPR $20.46
- UTHR $12.27
- Revenue Growth
- TPR 2.67
- UTHR 19.84
- 52 Week Low
- TPR $35.23
- UTHR $260.41
- 52 Week High
- TPR $90.85
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- TPR 71.51
- UTHR 58.34
- Support Level
- TPR $71.99
- UTHR $290.02
- Resistance Level
- TPR $80.99
- UTHR $319.40
- Average True Range (ATR)
- TPR 2.39
- UTHR 9.71
- MACD
- TPR 1.41
- UTHR 2.88
- Stochastic Oscillator
- TPR 85.43
- UTHR 70.34
About TPR Tapestry Inc.
Coach, Kate Spade, and Stuart Weitzman are New York City-based Tapestry's fashion and accessory brands. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (64% of fiscal 2024 sales), Europe, Asia, and elsewhere. Coach (76% of sales) is best known for affordable luxury leather products. Kate Spade (20%) is known for colorful patterns and graphics. Both Coach and Kate Spade specialize in women's handbags and accessories, 69% of Tapestry's fiscal 2024 sales. Stuart Weitzman (4%) generates virtually all its revenue from women's luxury footwear.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.